SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences trades with traction on the bourses

08 Oct 2014 Evaluate

Suven Life Sciences is currently trading at Rs. 183.00, up by 3.85 points or 2.15% from its previous closing of Rs. 179.15 on the BSE.

The scrip opened at Rs. 179.70 and has touched a high and low of Rs. 183.50 and Rs. 177.00 respectively. So far 69666 shares were traded on the counter.

The BSE group 'B ' stock of face value Rs. 1 has touched a 52 week high of Rs. 229.80 on 08-Sep-2014 and a 52 week low of Rs. 44.50 on 10-Oct-2013.

Last one week high and low of the scrip stood at Rs. 186.00 and Rs. 174.75 respectively. The current market cap of the company is Rs. 2094.16 crore.

The promoters holding in the company stood at 64.76% while Institutions and Non-Institutions held 1.42% and 33.82% respectively.  Suven Life Sciences has been selected as one of the ‘Best Under A Billion’ companies by Forbes Asia 2014. Forbes Asia’s ‘Best Under A Billion’ list highlights 200 of the best small and midsized listed companies in Asia Pacific with annual revenue under $1 billion. To qualify for the selection, companies must have revenue between $5 million and $1 billion, positive net income and be publicly traded for at least a year.

From a universe of 17,000 companies, qualified candidates are screened on sales growth, earnings growth and return on equity. The result is a final list featuring 200 exceptional small and midsized companies from Asia Pacific.

In recognition of the achievement of these 200 ‘Best Under A Billion’ Companies, Forbes Asia is organizing an Award Ceremony and the company will receive this award on December 09, 2014 in Bangkok, Thailand.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.

 

Suven Life Sciences Share Price

195.90 -0.10 (-0.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×